Geneva Partners’s Merck MRK Stock Holding History

Geneva Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21,165	Closed	-$2.62M	–	79
2024 Q2	$2.62M	Buy	21,165 +951	+5%	+$123K	1.08%	32
2024 Q1	$2.67M	Sell	20,214 -300	-1%	-$37K	1.18%	32
2023 Q4	$2.24M	Sell	20,514 -21,390	-51%	-$2.22M	1.24%	30
2023 Q3	$4.31M	Sell	41,904 -8,169	-16%	-$880K	2.86%	17
2023 Q2	$5.78M	Sell	50,073 -1,173	-2%	-$133K	3.77%	6
2023 Q1	$5.45M	Sell	51,246 -2,114	-4%	-$228K	4.67%	3
2022 Q4	$5.92M	Buy	53,360 +48,259	+946%	+$4.93M	5.59%	2
2022 Q3	$439K	Buy	+5,101	New	+$455K	0.5%	45

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geneva Partners's MRK Position: Q3 2024 in Review

Geneva Partners sold out of Merck (MRK) in Q3 2024, closing a stake of 21,165 shares — an estimated $2.62M sold.

Geneva Partners first reported a position in MRK in Q3 2022 and held it in 8 quarters. The position peaked at $5.92M in Q4 2022. 3,490 funds tracked by Wall St. Rank hold MRK as of Q3 2024.

Geneva Partners reported no remaining Merck position as of Q3 2024 after selling out during the quarter.
Geneva Partners sold 21,165 Merck shares in Q3 2024, an estimated $2.62M.
Geneva Partners first reported a position in Merck in Q3 2022 and held it in 8 quarters.
Geneva Partners's Merck position peaked at $5.92M in Q4 2022.
3,490 funds tracked by Wall St. Rank held Merck as of Q3 2024.

Based on Geneva Partners's 13F filing for Q3 2024, filed 30 Oct 2024.